Title: Mapping of the available standards against the regulatory needs for nanomedicines
Authors: HALAMODA KENZAOUI BLANKAHOLZWARTH UWEROEBBEN GERTBOGNI ALESSIABREMER SUSANNE
Citation: WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY vol. 11 no. 1 p. 1-17
Publisher: WILEY-BLACKWELL
Publication Year: 2019
JRC N°: JRC108980
ISSN: 1939-5116 (online)
URI: https://doi.org/10.1002/wnan.1531
http://publications.jrc.ec.europa.eu/repository/handle/JRC108980
DOI: 10.1002/wnan.1531
Type: Articles in periodicals and books
Abstract: Appropriate documentary standards and reference materials are crucial building blocks for the development of innovative products. In order to support the emerging sector of nanomedicine, relevant standards must be identified and/or developed before the products will enter into the regulatory approval process. The anticipation of standardization needs requires a good understanding on the regulatory information requirements that can be triggered by the particularities of nanomedicines. However, robust datasets allowing firm conclusions on regulatory demands are not yet available due to a lack of regulatory experience with innovative products. Such a catch‐22 situation can only be advanced in an iterative process by monitoring continuously the scientific evidence and by promoting intensive knowledge exchange between all involved stakeholders. In this study, we have compiled information requirements released by regulatory scientists so far and mapped it against available standards that could be of relevance for nanomedicines. Our gap analysis clearly demonstrated that for some endpoints such as drug release/loading and the interaction of nanomedicines with the immune system no standards are available so far. The emerging nanomedicine sector could benefit from cross‐sector collaboration and review the suitability of standards that have been developed for nanomaterials used for other industrial applications. Only a concerted action of all parties can lead to a smooth translation of nanomedicines to clinical application and to the market. This is in particular important because nanotechnology‐based drug delivery systems are key for the development and implementation of personalized medicine.
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.